A Phase 1 trial testing RAG-17, a potential ALS therapy for people carrying SOD1 mutations, has dosed its first participant.
This content is sponsored by Mitsubishi Tanabe Pharma America, Inc. (MTPA) and is intended for US audiences only. Any other ...
Despite the lower ALS risk, heart and metabolism problems are tied to faster disease progression and worse survival in the ...
People with amyotrophic lateral sclerosis (ALS) who get a feeding tube placed after loosing a lot of weight are more likely to die within a few months than those who receive feeding support before ...
The creatinine-to-cystatin C ratio may indicate the risk of developing amyotrophic lateral sclerosis, a large-scale database ...
Columnist Kristin Neva is applying something she learned about finding moments to appreciate during winter to life with ALS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback